Predicted to enable cytokine activity; protein heterodimerization activity; and protein homodimerization activity. Involved in cellular response to glucocorticoid stimulus; positive regulation of transcription by RNA polymerase II; and response to amino acid. Located in extracellular space. Used to study anti-basement membrane glomerulonephritis; congestive heart failure; myocarditis; pleurisy; and uveitis. Biomarker of several diseases, including acute necrotizing pancreatitis; inflammatory bowel disease (multiple); lung disease (multiple); myocardial infarction (multiple); and periodontal disease (multiple). Human ortholog(s) of this gene implicated in Mycobacterium avium complex disease; autoimmune disease (multiple); bronchial disease (multiple); macular degeneration; and rhinitis (multiple). Orthologous to human IL17A (interleukin 17A); PARTICIPATES IN interleukin-23 signaling pathway; interleukin-27 signaling pathway; INTERACTS WITH 1-chloro-2,4-dinitrobenzene; 2,4,6-trinitrobenzenesulfonic acid; 7,12-dimethyltetraphene.
resveratrol inhibits the reaction [tetrandrine inhibits the reaction [COL2A1 protein results in increased expression of IL17A protein]] and tetrandrine inhibits the reaction [COL2A1 protein results in increased expression of IL17A protein]
Estradiol inhibits the reaction [Halothane results in increased expression of IL17A protein] and fulvestrant inhibits the reaction [Estradiol inhibits the reaction [Halothane results in increased expression of IL17A protein]]
2-methyl-2H-pyrazole-3-carboxylic acid (2-methyl-4-o-tolylazophenyl)amide inhibits the reaction [Tetrachlorodibenzodioxin results in increased secretion of IL17A protein] more ...
[Trinitrobenzenesulfonic Acid results in increased susceptibility to [Ionomycin co-treated with Tetradecanoylphorbol Acetate]] which results in increased expression of IL17A protein
Methylene Blue inhibits the reaction [Trinitrobenzenesulfonic Acid results in increased expression of IL17A protein] and Sulfasalazine inhibits the reaction [Trinitrobenzenesulfonic Acid results in increased expression of IL17A protein]
Trinitrobenzenesulfonic Acid results in increased expression of IL17A mRNA and Trinitrobenzenesulfonic Acid results in increased expression of IL17A protein
[Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in decreased expression of IL17A mRNA and Rosmarinic Acid inhibits the reaction [[Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in decreased expression of IL17A mRNA]
[Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in decreased expression of IL17A mRNA and Rosmarinic Acid inhibits the reaction [[Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in decreased expression of IL17A mRNA]
4-phenylbutyric acid inhibits the reaction [3-acetyldeoxynivalenol results in increased expression of and results in increased secretion of IL17A protein] and 4-phenylbutyric acid inhibits the reaction [3-acetyldeoxynivalenol results in increased expression of IL17A mRNA]
Alloxan results in increased expression of and results in increased secretion of IL17A protein and platycodin D inhibits the reaction [Alloxan results in increased expression of and results in increased secretion of IL17A protein]
[deoxynivalenol results in increased susceptibility to Antigens] which results in increased expression of IL17A protein and [ochratoxin A results in increased susceptibility to Antigens] which results in increased expression of IL17A protein
[Arsenic results in increased abundance of Cacodylic Acid] which affects the expression of IL17A mRNA and Arsenic results in decreased secretion of and results in decreased expression of IL17A protein
[Arsenic results in increased abundance of Cacodylic Acid] which affects the expression of IL17A mRNA and Arsenic results in decreased secretion of and results in decreased expression of IL17A protein
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of IL17A mRNA and Acetylcysteine inhibits the reaction [Azoxymethane results in increased expression of IL17A protein]
2-methyl-2H-pyrazole-3-carboxylic acid (2-methyl-4-o-tolylazophenyl)amide inhibits the reaction [bisphenol A affects the secretion of IL17A protein] and Cholecalciferol inhibits the reaction [bisphenol A results in increased secretion of IL17A protein]
2-methyl-2H-pyrazole-3-carboxylic acid (2-methyl-4-o-tolylazophenyl)amide inhibits the reaction [4 and 4'-bisphenol F results in increased secretion of IL17A protein]
Budesonide inhibits the reaction [Ozone results in increased expression of IL17A protein] and Progesterone promotes the reaction [Budesonide inhibits the reaction [Ozone results in increased expression of IL17A protein]]
[ITPR3 mutant form results in increased susceptibility to Cadmium] which results in increased expression of IL17A mRNA and Cadmium promotes the reaction [ITPR3 mutant form results in increased expression of IL17A mRNA]
Cannabidiol inhibits the reaction [[myelin oligodendrocyte glycoprotein (35-55) results in increased susceptibility to myelin oligodendrocyte glycoprotein (35-55)] which results in increased expression of and results in increased secretion of IL17A protein]
[Air Pollutants results in increased abundance of [Carbon Monoxide co-treated with Nitrogen Oxides co-treated with Sulfur Dioxide]] which results in increased expression of IL17A protein
[celastrol co-treated with coomassie Brilliant Blue] inhibits the reaction [Acetaminophen results in increased expression of IL17A protein] and celastrol inhibits the reaction [Dextran Sulfate results in increased expression of IL17A protein]
[Dietary Fats co-treated with Choline deficiency] results in increased expression of IL17A protein and PANX1 gene mutant form inhibits the reaction [[Dietary Fats co-treated with Choline deficiency] results in increased expression of IL17A protein]
corosolic acid analog inhibits the reaction [Tetradecanoylphorbol Acetate results in increased expression of IL17A mRNA] and corosolic acid inhibits the reaction [Tetradecanoylphorbol Acetate results in increased expression of IL17A mRNA]
[Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in decreased expression of IL17A mRNA and Rosmarinic Acid inhibits the reaction [[Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in decreased expression of IL17A mRNA]
[cyanidin inhibits the reaction [[IL17A protein co-treated with Freund's Adjuvant] results in increased expression of and results in increased phosphorylation of STAT3 protein]] which results in increased expression of PIAS3 protein more ...
Fungal Polysaccharides inhibits the reaction [Cyclophosphamide results in decreased expression of IL17A protein] and Levamisole inhibits the reaction [Cyclophosphamide results in decreased expression of IL17A protein]
[lead chloride results in increased abundance of Lead] promotes the reaction [decabromobiphenyl ether results in increased expression of IL17A protein] and decabromobiphenyl ether promotes the reaction [[lead chloride results in increased abundance of Lead] which results in increased expression of IL17A protein]
[deoxynivalenol results in increased susceptibility to Antigens] which results in increased expression of IL17A protein and Celecoxib inhibits the reaction [deoxynivalenol results in increased expression of IL17A protein]
Dexamethasone inhibits the reaction [Ovalbumin results in increased expression of IL17A mRNA] and Dexamethasone inhibits the reaction [Ovalbumin results in increased expression of IL17A protein]
[Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in decreased expression of IL17A mRNA and Rosmarinic Acid inhibits the reaction [[Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in decreased expression of IL17A mRNA]
2-(1'H-indole-3'-carbonyl)thiazole-4-carboxylic acid methyl ester inhibits the reaction [Dextran Sulfate results in increased expression of IL17A protein] more ...
[Iodine co-treated with Dibutyl Phthalate] results in increased expression of IL17A protein and pyrazolanthrone inhibits the reaction [[Iodine co-treated with Dibutyl Phthalate] results in increased expression of IL17A protein]
Digoxin inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of IL17A mRNA] and Digoxin inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of IL17A protein]
[Iodine co-treated with Dibutyl Phthalate] results in increased expression of IL17A protein and pyrazolanthrone inhibits the reaction [[Iodine co-treated with Dibutyl Phthalate] results in increased expression of IL17A protein]
[Formaldehyde co-treated with diisononyl phthalate] promotes the reaction [OVAL protein results in increased secretion of [IL17A protein binds to IL17F protein]] and dehydroxymethylepoxyquinomicin inhibits the reaction [[Formaldehyde co-treated with diisononyl phthalate] promotes the reaction [OVAL protein results in increased secretion of [IL17A protein binds to IL17F protein]]]
ferulic acid inhibits the reaction [Imiquimod results in increased expression of IL17A mRNA] and ferulic acid inhibits the reaction [Imiquimod results in increased expression of IL17A protein]
[IL17A protein co-treated with Floxacillin] results in increased expression of MPO protein and IL17A protein promotes the reaction [Floxacillin results in increased expression of GPT protein]
[Formaldehyde co-treated with diisononyl phthalate] promotes the reaction [OVAL protein results in increased secretion of [IL17A protein binds to IL17F protein]] and dehydroxymethylepoxyquinomicin inhibits the reaction [[Formaldehyde co-treated with diisononyl phthalate] promotes the reaction [OVAL protein results in increased secretion of [IL17A protein binds to IL17F protein]]]
Glyburide promotes the reaction [Isoproterenol results in increased expression of IL17A protein] and pyrvinium inhibits the reaction [Glyburide promotes the reaction [Isoproterenol results in increased expression of IL17A protein]]
[morin co-treated with Indomethacin] inhibits the reaction [Freund's Adjuvant results in increased expression of IL17A mRNA] and Indomethacin inhibits the reaction [Freund's Adjuvant results in increased expression of IL17A mRNA]
[Trinitrobenzenesulfonic Acid results in increased susceptibility to [Ionomycin co-treated with Tetradecanoylphorbol Acetate]] which results in increased expression of IL17A protein
[lead chloride results in increased abundance of Lead] promotes the reaction [decabromobiphenyl ether results in increased expression of IL17A protein] more ...
[lead chloride results in increased abundance of Lead] promotes the reaction [decabromobiphenyl ether results in increased expression of IL17A protein] more ...
IL17A protein affects the reaction [[Melatonin co-treated with Fluorides] results in increased expression of IL10 mRNA] and Melatonin inhibits the reaction [Ozone promotes the reaction [Ovalbumin results in increased expression of IL17A protein]]
Methotrexate inhibits the reaction [Freund's Adjuvant results in increased expression of IL17A mRNA] and Methotrexate inhibits the reaction [Freund's Adjuvant results in increased expression of IL17A protein]
[morin co-treated with Indomethacin] inhibits the reaction [Freund's Adjuvant results in increased expression of IL17A mRNA] and morin inhibits the reaction [Freund's Adjuvant results in increased expression of IL17A mRNA]
Acetylcysteine inhibits the reaction [Azoxymethane results in increased expression of IL17A protein] and Acetylcysteine inhibits the reaction [Trichloroethylene results in increased expression of IL17A mRNA]
[[Air Pollutants results in increased abundance of Ozone] which results in increased expression of SAA3 mRNA] which results in increased expression of IL17A mRNA more ...
[Trinitrobenzenesulfonic Acid results in increased susceptibility to [Ionomycin co-treated with Tetradecanoylphorbol Acetate]] which results in increased expression of IL17A protein
platycodin D inhibits the reaction [[IL6 protein co-treated with TGFB1 protein] results in increased expression of and results in increased secretion of IL17A protein] and platycodin D inhibits the reaction [Alloxan results in increased expression of and results in increased secretion of IL17A protein]
pyrvinium inhibits the reaction [Glyburide promotes the reaction [Isoproterenol results in increased expression of IL17A protein]] and pyrvinium inhibits the reaction [Isoproterenol results in increased expression of IL17A protein]
Rosmarinic Acid inhibits the reaction [[Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in decreased expression of IL17A mRNA]
stannous mesoporphyrin inhibits the reaction [4-(4-(3-adamantan-1-ylureido)cyclohexyloxy)benzoic acid inhibits the reaction [Streptozocin results in increased expression of IL17A protein]]
[Air Pollutants results in increased abundance of [Carbon Monoxide co-treated with Nitrogen Oxides co-treated with Sulfur Dioxide]] which results in increased expression of IL17A protein
Carbon Tetrachloride results in increased secretion of and results in decreased expression of IL17A protein and ruxolitinib inhibits the reaction [Carbon Tetrachloride results in increased secretion of and results in decreased expression of IL17A protein]
tofacitinib inhibits the reaction [enterotoxin A and Staphylococcal results in increased expression of and results in increased secretion of IL17A protein]
Increased IL-17A expression in temporal artery lesions is a predictor of sustained response to glucocorticoid treatment in patients with giant-cell arteritis.
Neuroprotection effect of interleukin (IL)-17 secreted by reactive astrocytes is emerged from a high-level IL-17-containing environment during acute neuroinflammation.
Susceptibility to pulmonary disease due to Mycobacterium avium-intracellulare complex may reflect low IL-17 and high IL-10 responses rather than Th1 deficiency.
Efficacy and safety of secukinumab, a fully human anti-interleukin-17A monoclonal antibody, in patients with moderate-to-severe psoriatic arthritis: a 24-week, randomised, double-blind, placebo-controlled, phase II proof-of-concept trial.
Methylprednisolone inhibits IFN-gamma and IL-17 expression and production by cells infiltrating central nervous system in experimental autoimmune encephalomyelitis.
Enhancement of acute phase and inhibition of chronic phase of experimental autoimmune neuritis in Lewis rats by intranasal administration of recombinant mouse interleukin 17: potential immunoregulatory role.
IL-17 is a critical component of vaccine-induced protection against lung infection by lipopolysaccharide-heterologous strains of Pseudomonas aeruginosa.
Interleukin-17 sensitizes joint nociceptors to mechanical stimuli and contributes to arthritic pain through neuronal interleukin-17 receptors in rodents.
Systemic neutralization of IL-17A significantly reduces breast cancer associated metastasis in arthritic mice by reducing CXCL12/SDF-1 expression in the metastatic niches.
Sequential IL-23 and IL-17 and increased Mmp8 and Mmp14 expression characterize the progression of an experimental model of periodontal disease in type 1 diabetes.
A comparison of the effects of topical treatment of calcipotriol, camptothecin, clobetasol and tazarotene on an imiquimod-induced psoriasis-like mouse model.
Interleukin 17A promotes pneumococcal clearance by recruiting neutrophils and inducing apoptosis through a p38 mitogen-activated protein kinase-dependent mechanism in acute otitis media.
Effects of supplemental dietary arginine on the exogenous advanced glycosylation end product-induced interleukin-23/interleukin-17 immune response in rats.
Potassium channel changes of peripheral blood T-lymphocytes from Kazakh hypertensive patients in Northwest China and the inhibition effect towards potassium channels by telmisartan.
